Skip to main content

Advertisement

SpringerLink
Log in

Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Dyslipoproteinemia is common in lupus patients. In this study, we investigated the pattern of dyslipoproteinemia in the course of active systemic lupus erythematosus (SLE) in possible association with anti-double-stranded DNA (anti-dsDNA) antibodies. Forty-six lupus patients under 45 years old who fulfilled the American College of Rheumatology revised criteria for the classification of SLE were selected. The exclusion criteria were renal failure, nephrotic syndrome, thyroid or liver disease, diabetes mellitus, obesity, pregnancy and taking drugs that induce dyslipidemia. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Comparison of the lipid profiles, between active and inactive groups determined high levels of serum TG and VLDL and low levels of serum HDL in active group in comparison with inactive group(P < 0.05). The results indicated that the levels of TG and VLDL were significantly elevated in the patients with positive anti-dsDNA (P < 0.05). Although, the mean of serum HDL levels was also lower in patients with positive anti-dsDNA, the difference was not significant. This pattern of dyslipoproteinemia in active SLE may be associated with the autoimmune mechanisms especially in relation to the presence of anti-dsDNA antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363

    Article  PubMed  CAS  Google Scholar 

  2. Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83:503–508

    Article  PubMed  CAS  Google Scholar 

  3. Petri M (2000) Detection of coronary artery disease and role of traditional risk factors in the Hopkins lupus Cohort. Lupus 9(3):170–175

    Article  PubMed  CAS  Google Scholar 

  4. Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267

    PubMed  CAS  Google Scholar 

  5. Lahita RG, Rivkin E, Cavanagh I, Romano P (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574

    PubMed  CAS  Google Scholar 

  6. Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863

    PubMed  CAS  Google Scholar 

  7. Borba EF, Bonfá E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539

    PubMed  CAS  Google Scholar 

  8. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963

    Article  PubMed  CAS  Google Scholar 

  9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    PubMed  CAS  Google Scholar 

  10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Committee on prognosis studies in SLE. Derivation of the SLEDAI a: disease activity index for lupus patients. Arthritis Rheum 35:630–640

    PubMed  CAS  Google Scholar 

  11. Warnick GR, Benderson J, Albers JJ (1982) Dextran sulfate–Mg2 + precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1379–1388

    PubMed  CAS  Google Scholar 

  12. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin chem 18:499–502

    PubMed  CAS  Google Scholar 

  13. Gharavi AV, Lockshin MD (1997) Antiphospholipid antibodies. In: Rose NR, Macario EC, Folds JD, et al (eds) manual of clinical laboratory, 5th edn, ASM press Immunology, Washington DC, pp 949–953

    Google Scholar 

  14. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J (2003) Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/ tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533–2540

    Article  PubMed  CAS  Google Scholar 

  15. Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS (1995) Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 22:1347–1351

    PubMed  CAS  Google Scholar 

  16. Ginsberg HN (1990) Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am 19:211–228

    PubMed  CAS  Google Scholar 

  17. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron (2000) Metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033–1040

    Article  PubMed  CAS  Google Scholar 

  18. Beaumont JL, Berard M, Antonucci M, Delplanque B, Vranckx R (1997) Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. Atherosclerosis 26:67–77

    Article  Google Scholar 

  19. Alverson DC, Chase HP (1977) Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91:72–75

    Article  PubMed  CAS  Google Scholar 

  20. Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694

    Article  PubMed  CAS  Google Scholar 

  21. Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K,Tonozuka N,Hayashi T, Umeda M (2001) Anti- apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 28:990–995

    PubMed  CAS  Google Scholar 

  22. Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG (1998) Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7:355–360

    Article  PubMed  CAS  Google Scholar 

  23. Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391

    PubMed  CAS  Google Scholar 

  24. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18:17–22

    Article  PubMed  CAS  Google Scholar 

  25. Semb H, Peterson J, Tavernier J, Olivecrona T (1987) Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol chem 262:8390–8394

    PubMed  CAS  Google Scholar 

  26. Beutler BA, Cerami A (1985) Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 135:3969–3971

    PubMed  CAS  Google Scholar 

  27. Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, Cantell K (1982) Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2:68–73

    PubMed  CAS  Google Scholar 

  28. Kwiterovich PO Jr (1998) The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q–21Q

    Article  PubMed  CAS  Google Scholar 

  29. Third report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III): final report. Circulation 106:3143–3420

    Google Scholar 

Download references

Acknowledgment

We thank Dr. Farrokh Habibzadeh (M.D.) for his critical review of the manuscript. This work was supported by grant No: 1603, awarded by Shiraz University of Medical Sciences.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Immunology and Allergy, Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Sara Kashef

  2. Shiraz University of Medical Sciences, Shiraz, Iran

    Mohammad Mehdi Ghaedian

  3. Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran

    Akbar Rajaee

  4. Department of Immunology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

    Abbas Ghaderi

Authors
  1. Sara Kashef
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Mehdi Ghaedian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akbar Rajaee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abbas Ghaderi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara Kashef.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kashef, S., Ghaedian, M.M., Rajaee, A. et al. Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies. Rheumatol Int 27, 235–241 (2007). https://doi.org/10.1007/s00296-006-0195-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-006-0195-3

Keywords

Search

Navigation